1. A statement about an ingredient, read as a statement about a product
The letters rest on two provisions of the Federal Food, Drug, and Cosmetic Act. Under section 502(a), in the letters' words, "a drug is misbranded if its labeling is false or misleading in any particular". Under section 502(bb), "a compounded drug is misbranded if its advertising or promotion is false or misleading in any particular."
The letters apply both provisions to what a company's website says. The test they state is whether the wording misleads in any particular.
In the letters we read in full, the FDA does not dispute that the compounded product contains the ingredient named. Its objection is to what the comparison implies. A footnote in eleven letters of June 2026 states the difference the agency has in mind: "Compounded drug products are not FDA-approved drugs; they have not been evaluated by FDA for safety, effectiveness, or quality before marketing as is required for new drug applications (NDAs) or abbreviated new drug applications (ANDAs)."
2. The wording the letters quote
Each letter sets the company's wording in quotation marks. Across the 114 letters issued between September 9, 2025 and October 30, 2026, the comparison to an approved drug takes a small number of forms.
| Form | An example the FDA quotes | Letters |
|---|---|---|
| Same active ingredient | "It contains the same active ingredient as FDA-approved medications" | 48 |
| "Generic" beside a brand name | "SEMAGLUTIDE (GENERIC OZEMPIC/WEGOVY)" | 10 |
Two further forms appear and are not counted separately here. One reverses the comparison: "Ozempic, Mounjaro, and Wegovy contain the same active ingredients as our compounded versions (semaglutide and tirzepatide)." The other attaches approval to the ingredient: "All our treatments use FDA-approved active ingredients".
The word "same" appears in the quoted wording of 58 letters: 31 from September 2025, 16 from February 2026 and 11 from June 2026. The phrase "same active ingredient", singular or plural, accounts for 48 of them. A brand name appears somewhere in the quoted wording of 79 letters.
These are counts by pattern across the quoted passages, checked by reading a sample of the letters in full. The method is described in our count of the letters by claim type.
3. September 2025: the same as an approved product
All 58 letters of September 2025 answer the quoted wording in the same way. "Compounded drug products are not FDA-approved. Your claims imply that your products are the same as an FDA-approved product when they are not. As a result, these claims are false or misleading and your products are therefore misbranded".
Forty-six letters use that sentence as written. Twelve use the singular, "Your claim implies".
The sentence is not confined to wording that uses the word "same". Twenty-seven of the 58 letters quote no such wording. They quote a brand name printed beside the compounded product, or the word "generic", or a product described as a brand's "compounded version", and the FDA gives the same answer. On this evidence the agency treated sameness as an impression that several kinds of wording can create.
The September letters also say what the recipient should do with the wording. They ask for immediate action, "including, for example, ceasing and desisting from using the language cited above that misbrands the product".
4. 2026: approved, or otherwise evaluated
The sameness sentence appears in none of the 56 letters issued in February, June and October 2026.
The wording it answered did not go away. Twenty-seven of those letters quote a claim that uses the word "same", and in all 27 the FDA's answer is the other sentence. The February letters say: "Your claims imply that your products have been FDA-approved or otherwise evaluated for safety and effectiveness when they have not." The June and October letters say: "Your claims represent that the compounded drug products you offer have been FDA-approved or otherwise evaluated for safety and effectiveness when they have not." One form or the other appears in 42 letters of 2026.
The two answers differ. The first says the comparison implies equivalence with an approved product. The second says it implies that the compounded product has itself been approved, or evaluated in some other way. The letters do not explain the change, and we do not infer a reason for it. The practical observation is narrower. A phrase such as "the same active ingredient as" has been cited under both readings, and in each of the first three rounds.
5. A disclaimer has not been accepted as an answer
The letter of October 30, 2026 is the only one in the population that addresses a disclaimer. The company's pages and video said that a compounded preparation "may not itself be FDA-approved" and that compounded medications are not approved. The FDA's response was that these statements "do not cure the misleading overall impression created by these claims."
This is one letter, and it concerns one company's pages. It does show the standard the agency applied there. The question was the overall impression, and a true statement elsewhere on the page did not settle it.
6. What the letters do not say
We found no letter that offers wording the FDA would accept. Each lists the claims it cites as examples, and each says in some form that the list is not exhaustive.
We found no letter that says a company may never name the active ingredient of a compounded product. The letters object to claims in the context in which they found them, on pages that offered compounded products.
A warning letter is an allegation, and the recipient may respond. We have not followed the responses.
7. Limits of this paper
Counts were made on November 18, 2026 from the 114 letters as published on the FDA's website. The FDA's sentences are counted by exact match. The quoted wording is counted by pattern and checked by hand on 22 letters. Section 4's description of the two answers as different objections is our reading. This paper reports what has been cited and is not legal advice on what a company may say.
Sources
- FDA, Warning Letters index, 114 letters with "(Telehealth)" in the subject line, issued September 9, 2025, February 20, 2026, June 8, 2026 and October 30, 2026, read November 18, 2026.
- Federal Food, Drug, and Cosmetic Act, sections 502(a) and 502(bb), 21 U.S.C. 352(a) and 352(bb), as characterized in the letters.
- Veritura, "What the FDA's Warning Letters to Telehealth Companies Cite: A Count by Claim Type", November 18, 2026.
A company that wants its product pages read against the wording these letters cite can start with a free claims review.
We review documents. We do not test material.